- Deintensification to a fixed mixture of insulin glargine and lixisenatide as a way to modern antidiabetic therapy in patients with type 2 diabetes mellitus2020 | First Faculty of Medicine
- Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results2022 | First Faculty of Medicine
- Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis2023 | First Faculty of Medicine
- Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective2020 | First Faculty of Medicine
- An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus2022 | First Faculty of Medicine